Letter to the Editor.
作者信息
Li Yan, Schneider Lon S, Wang Guoqiao
机构信息
Department of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.
Department of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
出版信息
Alzheimers Dement. 2025 May;21(5):e70250. doi: 10.1002/alz.70250.
Abstract
摘要
相似文献
1
Letter to the Editor.致编辑的信。
Alzheimers Dement. 2025 May;21(5):e70250. doi: 10.1002/alz.70250.
2
An article on "letter to the editor".一篇关于“致编辑的信”的文章。
J Oral Maxillofac Pathol. 2023 Apr-Jun;27(2):254-256. doi: 10.4103/jomfp.jomfp_65_23. Epub 2023 Jul 13.
3
Authors' response to letter to the editor, letter to the editor: Authors' response to letter to the editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events.作者对编辑来信的回复，编辑来信：作者对编辑来信的回复：日本人类乳头瘤病毒免疫接种的安全性问题：名古屋市不良事件监测数据的分析与评估
Jpn J Nurs Sci. 2020 Jan;17(1):e12310. doi: 10.1111/jjns.12310. Epub 2019 Dec 2.
4
How to write an editorial letter?如何撰写编辑信函？
Turk J Urol. 2013 Sep;39(Suppl 1):41-3. doi: 10.5152/tud.2013.053.
5
Letter to the Editor - The implications of the professionalization of health promotion in Canada: a response to JR Graham's letter to the editor.给编辑的信——加拿大健康促进专业化的影响：对 JR Graham 给编辑的信的回应。
Health Promot Chronic Dis Prev Can. 2017 May;37(5):172-173. doi: 10.24095/hpcdp.37.5.05.
6
LETter To the EditoR Standards (LETTERS): Considerations for Authors, Reviewers, and Editors.致编辑的信：标准（信件）：作者、审稿人和编辑须知
J Korean Med Sci. 2024 Sep 30;39(37):e296. doi: 10.3346/jkms.2024.39.e296.
7
Letter #1 Response to letter to Editor by Dr. Sarkar et al. for' who said differentiating preeclampsia from COVID-19 infection was easy? Refers to PII: S2210-7789(21)00539-0 Letter #2 Response to letter to Editor by Dr. Hantoushzadeh et al. for' is COVID-19 disease a risk factor for preeclampsia? Should aspirin be considered for prophylaxis of preeclampsia in these patients?' Refers to PII: S2210-7789(21)00538-9.信件1：对Sarkar博士等人致编辑的信的回复，信的主题为“谁说区分先兆子痫和新冠病毒感染很容易？”，涉及编号：S2210 - 7789(21)00539 - 0
信件2：对Hantoushzadeh博士等人致编辑的信的回复，信的主题为“新冠病毒疾病是先兆子痫的危险因素吗？这些患者是否应考虑使用阿司匹林预防先兆子痫？”，涉及编号：S2210 - 7789(21)00538 - 9
Pregnancy Hypertens. 2022 Mar;27:94-95. doi: 10.1016/j.preghy.2021.11.002. Epub 2021 Nov 25.
8
Letter to the Editor Re: Author's Response to Letter to the Editor.致编辑的信：关于作者对致编辑信件的回复
Arch Phys Med Rehabil. 2020 Jun;101(6):1096-1097. doi: 10.1016/j.apmr.2019.12.022. Epub 2020 Mar 7.
9
Reply to Letter to the Editor: Author Response to Letter to the Editor.致编辑信件的回复：作者对致编辑信件的回应。
J Am Acad Orthop Surg. 2023 Feb 1;31(3):e133-e134. doi: 10.5435/JAAOS-D-21-00805. Epub 2021 Sep 16.
10
Letter to the Editor Regarding "Editor-in-Chief's April 2021 Letter on 'The Humility Button'".致编辑的信：关于“主编2021年4月关于‘谦逊按钮’的信”
World Neurosurg. 2022 May;161:209-210. doi: 10.1016/j.wneu.2022.02.127.
引用本文的文献
1
Response to letter to the editor.对编辑来信的回复。
Alzheimers Dement. 2025 May;21(5):e70251. doi: 10.1002/alz.70251.
本文引用的文献
1
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's disease.在评估阿尔茨海默病治疗的临床益处时避免因果欺诈。
Alzheimers Dement. 2025 Feb;21(2):e14457. doi: 10.1002/alz.14457. Epub 2025 Jan 27.
2
Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials.在阿尔茨海默病临床试验中估计节省治疗效果时的统计考虑因素。
Alzheimers Dement. 2024 Aug;20(8):5421-5433. doi: 10.1002/alz.14035. Epub 2024 Jun 21.
3
Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods.新型非线性模型在临床试验分析中的纵向数据应用：使用 SAS 进行频率派和贝叶斯方法的教程。
Stat Med. 2024 Jul 10;43(15):2987-3004. doi: 10.1002/sim.10089. Epub 2024 May 10.
4
Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials.阿尔茨海默病临床试验中相对变化与效应大小指标的比较。
J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):2-7. doi: 10.1136/jnnp-2023-331941.
5
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.两项早期阿尔茨海默病甘特纳单抗的 3 期临床试验。
N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.
6
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
7
Expectations and clinical meaningfulness of randomized controlled trials.随机对照试验的预期和临床意义。
Alzheimers Dement. 2023 Jun;19(6):2730-2736. doi: 10.1002/alz.12959. Epub 2023 Feb 7.
8
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
9
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease.散发性阿尔茨海默病临床试验的比例约束纵向数据分析模型
Alzheimers Dement (N Y). 2022 Apr 5;8(1):e12286. doi: 10.1002/trc2.12286. eCollection 2022.
Zotero 插件